source
- Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma ManagementAjai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.onclive · 2mo ago↗ source
- Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment DurationNew SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.onclive · 2mo ago↗ source
- Disease Assessment and Mutational Testing in Progressive CLLExperts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.onclive · 2mo ago